The Committee for Medicinal Products for Human Use (CHMP) has given positive opinion as a non-prescription product to GlaxoSmithKline’s alli (orlistat 60 mg). This takes the product to the stage of proposal for final approval by the European Commission. A marketing authorization will follow that. On the grant of license, alli 60 mg would become the first aid for weight loss to be available without prescription across Europe. It will be indicated for people above the age of 18 with a BMI more than 28 kg/m2.